|
|
The Neuromuscular
Disorders Program at Northwestern University Feinberg School of
Medicine is actively involved in multi-center drug trials. They
have participated in eleven ALS drug studies since 1993 and continue
to pursue participation in new trials. Robert Sufit, M.D., Senda Ajroud-Driss, M.D. and Pat
Casey, M.S., OTR/L, CCRC oversee the therapeutic clinical drug trials.
The Neuromuscular disorders Program is currently participating in a multi-center clinical research study sponsored by the National Institutes of Health (NIH) with Coenzyme Q10, a nutritional supplement, to evaluate its effect on maintaining functional abilities. Stage 1 has been completed; Stage 2 began in Spring 2007.
The center is looking forward to participation in the following prospective trials, which will be enrolling new patients once the trials have been initiated: |
| |
|
| 2006-2007 |
NeuroQOL (quality of life questionnaire study) |
| 2007 |
Effects of excercise and nutrition of quality of life |
| 2007 |
Coenzyme Q10 Stage 2 |
| 2007 |
Arimoclomol Phase II-III |
| 2008-2009 |
Ceftriaxone |
| |
|
| The
center is currently involved in the following multi-center drug
trials (these are closed to enrollment of new patients): |
| |
|
| 1998-2007
|
Xaliproden
long-term study |
| |
|
| The
center has been involved with the following multi-center drug
trials, only one of which as been approved by the FDA at this
time: |
| |
|
| 1993-1994
|
CNTF (Ciliary
neurotrophic factor) subcutaneous injection |
| 1993-1995
|
Riluzole
(Rilutek) oral medication |
| 1995-1996
|
Riluzole
early access program, prior to FDA approval |
| 1994-1995
|
BDNF (Brain-derived
neurotrophic factor) subcutaneous injection |
| 1996 |
Riluzole
FDA APPROVED |
| 1995-1997
|
BDNF (Brain-derived
neurotrophic factor) subcutaneous injection |
| 1996-1998 |
Xaliproden oral medication |
| 1998-2007 |
Xaliproden oral medication, long-term study |
| 1998-2000
|
BDNF (Brain-derived
neurotrophic factor) Intrathecal pump |
| 2001-2002 |
Avanir - Neurodex submitted to FDA, oral medication for pseudobulbar affect |
| 2003-2005 |
Novartis TCH346 oral medication |
| 2004-2006 |
Coenzyme Q10 Stage 1 oral nutritional supplement |
| 2005-2006 |
CYP1A2 and Riluzole |
For more information, contact Pat Casey, M.S., OTR/L, CCRC, Clinical Research Coordinator at pcasey1@nmff.org or (312) 695-0774
|
